Gene · 1134
CHRNA1: cholinergic receptor nicotinic alpha 1 subunit
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CHRNA1: cholinergic receptor nicotinic alpha 1 subunit. Genes, record 1134. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1134
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P02708 | Acetylcholine receptor subunit alpha | 457 | 15 | Ensembl, GeneID, HGNC |
Source UniProt
Patents28
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026114898 A | 2026-07-08 | 16 | P02708 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 41224 | P02708 | Espacenet |
| JP 2025539844 A | 2025-12-09 | 53 | P02708 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 1836 | P02708 | Espacenet |
| KR 1020250115413 A | 2025-07-30 | 53 | P02708 | Espacenet |
| JP 2025104819 A | 2025-07-10 | 36 | P02708 | Espacenet |
| WO 2025143139 A | 2025-07-03 | 36 | P02708 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 1836 | P02708 | Espacenet |
| US 11685954 B2 | 2023-06-27 | 166 | P02708 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 15030 | P02708 | Espacenet |
1 to 10 of 28
See all 28 patentsDrugs28
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATRACURIUM | CHEMBL1360 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| ATRACURIUM BESYLATE | CHEMBL1200527 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| CISATRACURIUM | CHEMBL1201248 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| CISATRACURIUM BESYLATE | CHEMBL1200641 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| DECAMETHONIUM | CHEMBL1190 | Muscle-type nicotinic acetylcholine receptor partial agonist | PARTIAL AGONIST | ChEMBL |
| DECAMETHONIUM BROMIDE | CHEMBL1134 | Muscle-type nicotinic acetylcholine receptor partial agonist | PARTIAL AGONIST | ChEMBL |
| DOXACURIUM | CHEMBL1237123 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| DOXACURIUM CHLORIDE | CHEMBL1237099 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| GALLAMINE | CHEMBL360055 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| GALLAMINE TRIETHIODIDE | CHEMBL1200993 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
1 to 10 of 28
See all 28 drugsTrials47
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07271472 | ROCURONIUM | ClinicalTrials.gov | ||
| NCT07143799 | CISATRACURIUM | ClinicalTrials.gov | ||
| NCT07121699 | ROCURONIUM | ClinicalTrials.gov | ||
| NCT07035301 | ROCURONIUM | ClinicalTrials.gov | ||
| NCT07033442 | ROCURONIUM | ClinicalTrials.gov | ||
| NCT06714981 | ROCURONIUM BROMIDE | ClinicalTrials.gov | ||
| NCT06514209 | CISATRACURIUM | ClinicalTrials.gov | ||
| NCT06214169 | CISATRACURIUM | ClinicalTrials.gov | ||
| NCT06212492 | CISATRACURIUM | ClinicalTrials.gov | ||
| NCT06203405 | CISATRACURIUM | ClinicalTrials.gov |
1 to 10 of 47
See all 47 trialsNIH grants571
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CHRNA1 papers | Newest fiscal year |
|---|---|---|---|
| U54NS115054 | Rare Disease Network for Myasthenia Gravis | 3 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 2 | 2025 |
| P40OD010440 | Caenorhabditis Genetics Center | 2 | 2025 |
| R01AI114780 | Mechanisms of autoimmunity in myasthenia gravis | 2 | 2025 |
| T15LM007088 | Research Training in Biomedical Informatics and Data Science at Oregon Health & Science University | 2 | 2025 |
| U10AA008401 | Collaborative Study on the Genetics of Alcoholism (COGA). | 2 | 2025 |
| ZIACL090034 | Mechanisms of Pain and Immune Processes | 2 | 2025 |
| ZIADE000704 | Clinical and Mechanistic Investigations of Salivary Gland Dysfunction | 2 | 2025 |
| KL2TR001862 | Institutional Career Development Core | 1 | 2025 |
| P01AG019724 | Frontotemporal Dementia: Genes, Images, and Emotions | 1 | 2025 |
1 to 10 of 571Source NIH's project files
See all 571 nih grantsPapers889
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| NMJ-associated transcriptomic remodeling correlates with disease severity in juvenile dermatomyositis. | Inflamm Res | 2026 | 42700229 | PubTator, text mining | PubMed |
| Multi-omics identifies promoter methylation and gene expression changes associated with human skeletal muscle atrophy. | Exp Physiol | 2026 | 42636425 | PubTator, text mining | PubMed |
| CHRNA gene alterations in epilepsy: A systematic review of alpha subunit associations with ADSHE, SeLIE, and SeLECTS. | Epilepsy Res | 2026 | 42607591 | PubTator, text mining | PubMed |
| Integrative multi-omics and machine learning identify CHRNA1 putative circadian-immune hub in COPD. | PLoS One | 2026 | 42536689 | PubTator, text mining | PubMed |
| Congenital myasthenic syndromes in a Southeast Asian adult neurology clinic: a long road to diagnosis and therapy. | BMC Neurol | 2026 | 42469681 | PubTator, text mining | PubMed |
| Hsa_circ_0065149 mediates the ceRNA network pathway: Research on the mechanism regulating myasthenia gravis. | J Mol Neurosci | 2026 | 42171932 | PubTator, text mining | PubMed |
| Hidden diagnoses among patients with double seronegative myasthenia gravis. | Front Neurol | 2026 | 41940306 | PubTator, text mining | PubMed |
| Non-pterygium Escobar syndrome from compound-heterozygous CHRNG variants: genotype-phenotype insights. | Hum Genome Var | 2026 | 41826296 | PubTator, text mining | PubMed |
| Telitacicept for refractory AChR-positive generalized myasthenia gravis: a retrospective real-world study. | Front Immunol | 2026 | 41737228 | PubTator, text mining | PubMed |
| PGVDA: a pathway-aggregated genetic dosage framework for interpretable disease classification using machine learning. | Brief Bioinform | 2026 | 41632594 | PubTator, text mining | PubMed |
1 to 10 of 889
See all 889 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1134
GET https://conductscience.org/api/genes/v1/1134/patents?page=2